Emergent BioSolutions Inc. (NYSE: EBS) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $288M. The Maz Rating grades it against the other companies in its sector.
Emergent BioSolutions Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $5.61, Emergent BioSolutions Inc. trades at 0.4x sales and 0.9x book value. Over the last twelve months it generated about $641M of revenue and a net loss of $256M. It runs a gross margin of 41.6%, an operating margin of -26.0% and a net margin of -40.2%. It shows return on equity of -61.3%, return on invested capital of -19.3% and a free cash flow yield of 65.1%. On the balance sheet: a debt-to-equity ratio of 1.62 and a current ratio of 4.58. Over the past 52 weeks the share price ranged from $4.36 to $14.06, with a beta of 2.37.
Emergent BioSolutions Inc. does not currently pay a dividend.
15 Wall Street analyst ratings cover the stock: 11 Buy, 3 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Emergent BioSolutions Inc. (EBS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 156.9% / 30% · (Cash+Inv) / Mkt Cap (36m) 54.3% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 156.9% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 54.3% / 33% · Receivables / Mkt Cap (36m) 24.0% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 156.9% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 54.3% / 33.33% · Receivables / Mkt Cap (24m) 24.0% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 47.0% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 14.3% / 33.33% · Receivables / Avg Assets (4Q) 9.96% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 51.0% / 33.33% · (Cash+ST Inv) / Total Assets 17.7% / 33.33% · (Cash+Recv) / Total Assets 25.4% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, Emergent BioSolutions Inc. (EBS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Emergent BioSolutions Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m) and (Cash+Inv) / Mkt Cap (36m).
Emergent BioSolutions Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.